Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Новый интегральный энтезиально-коморбидный индекс оценки активности псориатического артрита
Новый интегральный энтезиально-коморбидный индекс оценки активности псориатического артрита
Корсакова Ю.Л., Коротаева Т.В., Логинова Е.Ю., Губарь Е.Е., Воробьева Л.Д., Глухова С.И., Насонов Е.Л. Новый интегральный энтезиально-коморбидный индекс оценки активности псориатического артрита. Терапевтический архив. 2023;95(5):404–409. DOI: 10.26442/00403660.2023.05.202197
© ООО «КОНСИЛИУМ МЕДИКУМ», 2023 г.
© ООО «КОНСИЛИУМ МЕДИКУМ», 2023 г.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Цель. Разработать интегральный индекс оценки активности псориатического артрита (ПсА).
Материалы и методы. Исследованы 117 больных ПсА: м/ж: 63/54, средний возраст – 44±11 лет, длительность псориаза (Пс) – 213±153 мес, ПсА – 73,4±78,5 мес. Определяли число болезненных (из 68) и припухших (из 66) суставов (ЧБС, ЧПС), LEI, болезненность подошвенной фасции (ПФ), распространенность Пс, наличие Пс ногтей, индекс массы тела (ИМТ, кг/м2), скорость оседания эритроцитов (СОЭ), С-реактивный белок (СРБ), DAPSA, FACIT-F. Использовали параметрические и непараметрические методы статистики, корреляционный и ROC-анализы.
Результаты. Средние – DAPSA – 38±21, ЧБС – 14,2±10,6, ЧПС – 10,6±8,3, СОЭ – 30,5±29,5 мм/ч, СРБ – 23,3±29 мг/л, LEI – 1,2±1,5, FACIT-F – 32±11, ИМТ – 27,4±6,2 кг/м2. Выявлена значимая положительная корреляция DAPSA с ИМТ, возрастом, СОЭ, длительностью ПсА и Пс, ЧБС, ЧПС, LEI, наличием энтезита ПФ, распространенностью Пс, наличием Пс ногтей и отрицательная корреляция с FACIT-F и мужским полом. На основании прогностической модели параметров создан Энтезиально-Коморбидный Индекс Активности ПсА (ЭКИАПсА): 3,81×LEI+3,72×ПФ+0,54×Возраст-0,25×FACIT-F+7,36×BSA+7,94×Длительность ПсА+5,5×Пс ногтей+0,32×ИМТ-3,52, где LEI – Лидский энтезиальный индекс; ПФ – наличие болезненности ПФ; Возраст – возраст больного; FACIT-F – шкала усталости; BSA<3%=0, ≥3%=1; длительность ПсА≤2 лет=0, >2 лет=1; наличие Пс ногтей=1, отсутствие=0; ЭКИАПсА≥28 баллов соответствует высокой активности ПсА по DAPSA≥28. ROC-анализ чувствительности и специфичности прогностической модели продемонстрировал высокую точность индекса: площадь под ROC-кривой – 0,768, 95% доверительный интервал 0,624–0,913.
Заключение. Новый индекс оценки активности ПсА соответствует существующим и учитывает клиническую гетерогенность и коморбидность заболевания.
Ключевые слова: активность псориатического артрита, новый энтезиально-коморбидный индекс активности псориатического артрита (ЭКИАПсА).
Materials and methods. 117 patients with PsA (M/F – 63/54) were included. Patients’ age 44±11 years, psoriasis (Ps) duration – 213±153 months, PsA duration – 73.4±78.5 months. Patients underwent standard clinical examination of PsA activity: tender (out of 68) and swollen (out of 66) joint counts (TJC, SJC), LEI, tenderness of the plantar fascia (PF), skin lesion severity (BSA), presence of nail Ps, body mass index (BMI), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), DAPSA, FACIT-F. Parametric and nonparametric statistic methods, correlation and ROC analysis were used.
Results. Mean DAPSA was 38±21, TJC – 14.2±10.6, SJC – 10.6±8.3, ESR – 30.5±29.5 mm/h, CRP – 23.3±29 mg/l, LEI – 1.2±1.5, FACIT-F – 32±11, BMI – 27.4±6.2 kg/m2. The following significant positive correlations were revealed: between DAPSA and BMI, patients’ age, ESR, PsA and Ps duration, TJC, SJC, LEI, presence of PF enthesitis, skin lesion severity, presence of nail Ps. A negative correlation between FACIT-F and male sex was found. Based on the predictive model of parameters, the Entesial-Comorbid Index of PsA (ECIPsA) was created: 3.81×LEI+13.72×PF+0.54×Age-0.25×FACIT-F+7.36×BSA+7.94×PsA duration+5.5×Nail Ps+0.32×BMI-3.52, namely LEI – Leeds Enthesial Index; PF – pain in the PF; patient’s age; FACIT-F – fatigue scale; BSA<3%=0, ≥3%=1; PsA duration≤2 years=0, >2 years=1; presence of nail Ps=1, absence=0; ECIPsA≥28 corresponds with high PsA activity according to DAPSA≥28. ROC analysis of sensitivity and specificity of the prognostic model demonstrated high correctness of the index: the area under the ROC curve was 0.768, 95% confidence interval (0.624–0.913).
Conclusion. The new PsA activity index corresponds to the existing ones and takes into consideration the clinical heterogeneity and comorbidity of the disease.
Keywords: psoriatic arthritis activity, new enthesial-comorbidity index of psoriatic arthritis activity (ECIPsA)
Материалы и методы. Исследованы 117 больных ПсА: м/ж: 63/54, средний возраст – 44±11 лет, длительность псориаза (Пс) – 213±153 мес, ПсА – 73,4±78,5 мес. Определяли число болезненных (из 68) и припухших (из 66) суставов (ЧБС, ЧПС), LEI, болезненность подошвенной фасции (ПФ), распространенность Пс, наличие Пс ногтей, индекс массы тела (ИМТ, кг/м2), скорость оседания эритроцитов (СОЭ), С-реактивный белок (СРБ), DAPSA, FACIT-F. Использовали параметрические и непараметрические методы статистики, корреляционный и ROC-анализы.
Результаты. Средние – DAPSA – 38±21, ЧБС – 14,2±10,6, ЧПС – 10,6±8,3, СОЭ – 30,5±29,5 мм/ч, СРБ – 23,3±29 мг/л, LEI – 1,2±1,5, FACIT-F – 32±11, ИМТ – 27,4±6,2 кг/м2. Выявлена значимая положительная корреляция DAPSA с ИМТ, возрастом, СОЭ, длительностью ПсА и Пс, ЧБС, ЧПС, LEI, наличием энтезита ПФ, распространенностью Пс, наличием Пс ногтей и отрицательная корреляция с FACIT-F и мужским полом. На основании прогностической модели параметров создан Энтезиально-Коморбидный Индекс Активности ПсА (ЭКИАПсА): 3,81×LEI+3,72×ПФ+0,54×Возраст-0,25×FACIT-F+7,36×BSA+7,94×Длительность ПсА+5,5×Пс ногтей+0,32×ИМТ-3,52, где LEI – Лидский энтезиальный индекс; ПФ – наличие болезненности ПФ; Возраст – возраст больного; FACIT-F – шкала усталости; BSA<3%=0, ≥3%=1; длительность ПсА≤2 лет=0, >2 лет=1; наличие Пс ногтей=1, отсутствие=0; ЭКИАПсА≥28 баллов соответствует высокой активности ПсА по DAPSA≥28. ROC-анализ чувствительности и специфичности прогностической модели продемонстрировал высокую точность индекса: площадь под ROC-кривой – 0,768, 95% доверительный интервал 0,624–0,913.
Заключение. Новый индекс оценки активности ПсА соответствует существующим и учитывает клиническую гетерогенность и коморбидность заболевания.
Ключевые слова: активность псориатического артрита, новый энтезиально-коморбидный индекс активности псориатического артрита (ЭКИАПсА).
________________________________________________
Materials and methods. 117 patients with PsA (M/F – 63/54) were included. Patients’ age 44±11 years, psoriasis (Ps) duration – 213±153 months, PsA duration – 73.4±78.5 months. Patients underwent standard clinical examination of PsA activity: tender (out of 68) and swollen (out of 66) joint counts (TJC, SJC), LEI, tenderness of the plantar fascia (PF), skin lesion severity (BSA), presence of nail Ps, body mass index (BMI), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), DAPSA, FACIT-F. Parametric and nonparametric statistic methods, correlation and ROC analysis were used.
Results. Mean DAPSA was 38±21, TJC – 14.2±10.6, SJC – 10.6±8.3, ESR – 30.5±29.5 mm/h, CRP – 23.3±29 mg/l, LEI – 1.2±1.5, FACIT-F – 32±11, BMI – 27.4±6.2 kg/m2. The following significant positive correlations were revealed: between DAPSA and BMI, patients’ age, ESR, PsA and Ps duration, TJC, SJC, LEI, presence of PF enthesitis, skin lesion severity, presence of nail Ps. A negative correlation between FACIT-F and male sex was found. Based on the predictive model of parameters, the Entesial-Comorbid Index of PsA (ECIPsA) was created: 3.81×LEI+13.72×PF+0.54×Age-0.25×FACIT-F+7.36×BSA+7.94×PsA duration+5.5×Nail Ps+0.32×BMI-3.52, namely LEI – Leeds Enthesial Index; PF – pain in the PF; patient’s age; FACIT-F – fatigue scale; BSA<3%=0, ≥3%=1; PsA duration≤2 years=0, >2 years=1; presence of nail Ps=1, absence=0; ECIPsA≥28 corresponds with high PsA activity according to DAPSA≥28. ROC analysis of sensitivity and specificity of the prognostic model demonstrated high correctness of the index: the area under the ROC curve was 0.768, 95% confidence interval (0.624–0.913).
Conclusion. The new PsA activity index corresponds to the existing ones and takes into consideration the clinical heterogeneity and comorbidity of the disease.
Keywords: psoriatic arthritis activity, new enthesial-comorbidity index of psoriatic arthritis activity (ECIPsA)
Полный текст
Список литературы
1. FitzGerald O, Ogdie A, Chandran V, et al. Psoriatic arthritis. Nat Rev Dis Primers. 2021;7(1):59. DOI:10.1038/s41572-021-00293-y
2. Gupta S, Syrimi Z, Hughes DM, Zhao SS. Comorbidities in psoriatic arthritis: asystematic review and meta-analysis. Rheumatol Int. 2021;41(2):275-84.
DOI:10.1007/s00296-020-04775-2
3. Coates LC, Merola JF, Mease PhJ, et al. Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis. Rheumatol. 2021;60:1137-47. DOI:10.1093/rheumatology/keaa271
4. Farkas F, Ikumi N, Elmamoun M, et al. Comparison of Composite Measure Remission Targets in Psoriatic Arthritis. J Rheumatol. 2021;48(8):1272-8. DOI:10.3899/jrheum.200556
5. Wervers K, Luime JJ, Tchetverikov I, et al. Comparison of disease activity measures in early psoriatic arthritis in usual care. Rheumatol (Oxford). 2019;58(12):2251-9. DOI:10.1093/rheumatology/kez215
6. Mumtaz A, Gallagher P, Kirby B, et al. Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis. 2011;70:272-7. DOI:10.1136/ard.2010.129379
7. Helliwell P, FitzGerald O, Fransen J, et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis. 2013;72(2):986-91.
8. Helliwell PJ, Coates LC, FitzGerald O, et al. Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease. Arthritis Res Ther. 2018;20(1):242. DOI:10.1186/s13075-018-1739-0
9. Kumthekar A, Ogdie A. Obesity and Psoriatic Arthritis: A Narrative Review. Rheumatol Ther. 2020;7:447-56. DOI:10.1007/s40744-020-00215-6
10. Ulus Y, Akyol Y, Bilgici1 A, Kuru O. The impact of the presence of fibromyalgia on fatigue in patients with psoriatic arthritis: comparison with controls. Advances Rheumatol. 2020;60:1. DOI:10.1186/s42358-019-0104-6
11. Li Sh-Sh, Du N, He Shi-H, et al. Exploring the Association Between History of Psoriasis (PSO) and Disease Activity in Patients with Psoriatic Arthritis (PsA). Rheumatol Ther. 2022;9(4):1079-90. DOI:10.1007/s40744-022-00455-8
12. Fragoulis GE, Nikiphorou E, McInnes IB, Siebert S. Does Age Matter in Psoriatic Arthritis? A Narrative Review. J Rheumatol. 2022;49(10):1085‑91. DOI:10.3899/jrheum.210349
13. Coates LC, Moverley AR, McParland L, et al. Effect of Tight Control of Inflammation in Early Psoriatic Arthritis (TICOPA): A UK Multicentre, Open-Label, Randomised Controlled Trial. Lancet. 2015;386(10012):2489-98. DOI:10.1016/S0140-6736(15)00347-5
14. Коротаева Т.В., Логинова Е.Ю., Гетия Т.С., Насонов Е.Л. Результаты применения стратегии «Лечение до достижения цели» у больных ранним псориатическим артритом через 1 год после начала терапии: данные исследования РЕМАРКА. Терапевтический архив. 2018;90(5):22-9 [Korotaeva TV, Loginova EYu, Getiya TS, Nasonov E.L. Results of one-year treat-to-target strategy in early psoriatic arthritis: data of an open-label REMARCA study. Terapevticheskii Arkhiv (Ter. Arkh.). 2018;90(5):22-9 (in Russian)]. DOI:10.26442/terarkh201890522-29
15. Schoels MM, Aletaha D, Alasti F, Smolen JS. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis. 2016;75(5):811. DOI:10.1136/annrheumdis-2015-207507
16. Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465-79. DOI:10.1038/s41584-022-00798-0
17. Landewe RM, van der Heijde D. Use of multidimensional composite scores in rheumatology: parsimony versus subtlety. Ann Rheum Dis. 2021;80:280-5.
DOI:10.1136/annrheumdis-2020-216999
18. Chandran V, Bhella S, Schentag C, Gladman D. Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis. Ann Rheum Dis. 2007;66(7):936-9. DOI:10.1136/ard.2006.065763
19. Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79:700-12. DOI:10.1136/annrheumdis-2020-217159
20. Sunar I, Ataman S, Nas K, et al. Enthesitis and its relationship with disease activity, functional status, and quality of life in psoriatic arthritis: a multi-center study. Rheumatol Int. 2020;40(2):283-94. DOI:10.1007/s00296-019-04480-9
21. Eder L, Farrer C, Jerome D. Is Enthesitis a Marker of Disease Severity in Early Psoriatic Arthritis? Arthritis Rheumatol. 2018;70(10). Available at: https://acrabstracts.org/abstract/is-enthesitis-a-marker-of-disease-severity-in-early-psoriatic-arth... Accessed: 05.09.2022.
22. Mease PJ, Etzel CJ, Huster WJ, et al. Understanding the association between skin involvement and joint activity in patients with psoriatic arthritis: experience from the Corrona Registry. RMD Open. 2019;5:e000867. DOI:10.1136/rmdopen-2018-000867
23. Губарь Е.Е., Корсакова Ю.Л., Логинова Е.Ю., и др. Поражение ногтей при псориатическом артрите. Данные общероссийского регистра. Научно-практическая ревматология. 2021;59(5):563‑70 [Gubar EE, Korsakova YuL, Loginova EYu, et al. Nail disease in psoriatic arthritis. Data from the Russian Psoriatic Arthritis Registry. Rheumatology Science and Practice. 2021;59(5):563-70 (in Russian)]. DOI:10.47360/1995-4484-2021-563-570
24. Mease PJ, Liu M, Rebello S, et al. Association of Nail Psoriasis With Disease Activity Measures and Impact in Psoriatic Arthritis: Data From the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. J Rheumatol. 2021;48(4):520-6. DOI:10.3899/jrheum.19092
25. Reich K, Sullivan J, Arenberger P, et al. Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial. Br J Dermatol. 2019;181(5):954-66. DOI:10.1111/bjd.17351
26. Gulati AM, Semb AG, Rollefstad S, et al. On the HUNT for cardiovascular risk factors and disease in patients with psoriatic arthritis: population-based data from the Nord-Trøndelag Health Study. Ann Rheum Dis. 2016;75(5):819-24. DOI:10.1136/annrheumdis-2014-206824
27. Haroon M, FitzGerald O. Psoriatic arthritis: complexities, comorbidities and implications for the clinic. Expert Rev Clin Immunol. 2016;12(4):405‑16. DOI:10.1586/1744666X.2016.1139453
28. di Minno MN, Peluso R, Iervolino S, et al. Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis. Arthritis Care Res. 2013;65(1):141-7. DOI:10.1002/acr.21711
29. Корсакова Ю.Л., Коротаева Т.В., Логинова Е.Ю., и др. Взаимосвязь ожирения, кардиометаболических нарушений и активности заболевания у больных псориатическим артритом: данные Общероссийского регистра. Терапевтический архив. 2021;93(5):573-80 [Korsakova YuL, Korotaeva TV, Loginova EIu, et al. The relationship between obesity, cardiometabolic disorders and disease activity in psoriatic arthritis patients: data from the Russian register. Terapevticheskii Arkhiv (Ter. Arkh.). 2021;93(5):573-80 (in Russian)]. DOI:10.26442/00403660.2021.05.200789
30. Korsakova Y, Gubar E, Loginova E, et al. The impact of number of comorbidities on achievement remission or low disease activity by DAPSA in psoriatic arthritis. Data from the Russian observational cohort. Ann Rheum Dis. 2022;81(1):871. DOI:10.1136/annrheumdis-2022-eular.3308
31. Корсакова Ю.Л., Логинова Е.Ю., Коротаева Т.В., и др. Бремя прогрессирования псориатического артрита. Данные общероссийского регистра. Терапевтический архив. 2022;94(5):622-7 [Korsakova YuL, Loginova EYu, Korotaeva TV, et al. The burden of progression of psoriatic arthritis. All-Russian register data. Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(5):622-7 (in Russian)]. DOI:10.26442/00403660.2022.05.201506
32. Gossec L, Walsh JA, Michaud K, et al. Impact of Fatigue on Health-Related Quality of Life and Work Productivity in Psoriatic Arthritis: Findings From a Real-World Survey. J Rheumatol. 2022. DOI:10.3899/jrheum.211288
2. Gupta S, Syrimi Z, Hughes DM, Zhao SS. Comorbidities in psoriatic arthritis: asystematic review and meta-analysis. Rheumatol Int. 2021;41(2):275-84.
DOI:10.1007/s00296-020-04775-2
3. Coates LC, Merola JF, Mease PhJ, et al. Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis. Rheumatol. 2021;60:1137-47. DOI:10.1093/rheumatology/keaa271
4. Farkas F, Ikumi N, Elmamoun M, et al. Comparison of Composite Measure Remission Targets in Psoriatic Arthritis. J Rheumatol. 2021;48(8):1272-8. DOI:10.3899/jrheum.200556
5. Wervers K, Luime JJ, Tchetverikov I, et al. Comparison of disease activity measures in early psoriatic arthritis in usual care. Rheumatol (Oxford). 2019;58(12):2251-9. DOI:10.1093/rheumatology/kez215
6. Mumtaz A, Gallagher P, Kirby B, et al. Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis. 2011;70:272-7. DOI:10.1136/ard.2010.129379
7. Helliwell P, FitzGerald O, Fransen J, et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis. 2013;72(2):986-91.
8. Helliwell PJ, Coates LC, FitzGerald O, et al. Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease. Arthritis Res Ther. 2018;20(1):242. DOI:10.1186/s13075-018-1739-0
9. Kumthekar A, Ogdie A. Obesity and Psoriatic Arthritis: A Narrative Review. Rheumatol Ther. 2020;7:447-56. DOI:10.1007/s40744-020-00215-6
10. Ulus Y, Akyol Y, Bilgici1 A, Kuru O. The impact of the presence of fibromyalgia on fatigue in patients with psoriatic arthritis: comparison with controls. Advances Rheumatol. 2020;60:1. DOI:10.1186/s42358-019-0104-6
11. Li Sh-Sh, Du N, He Shi-H, et al. Exploring the Association Between History of Psoriasis (PSO) and Disease Activity in Patients with Psoriatic Arthritis (PsA). Rheumatol Ther. 2022;9(4):1079-90. DOI:10.1007/s40744-022-00455-8
12. Fragoulis GE, Nikiphorou E, McInnes IB, Siebert S. Does Age Matter in Psoriatic Arthritis? A Narrative Review. J Rheumatol. 2022;49(10):1085‑91. DOI:10.3899/jrheum.210349
13. Coates LC, Moverley AR, McParland L, et al. Effect of Tight Control of Inflammation in Early Psoriatic Arthritis (TICOPA): A UK Multicentre, Open-Label, Randomised Controlled Trial. Lancet. 2015;386(10012):2489-98. DOI:10.1016/S0140-6736(15)00347-5
14. Коротаева Т.В., Логинова Е.Ю., Гетия Т.С., Насонов Е.Л. Результаты применения стратегии «Лечение до достижения цели» у больных ранним псориатическим артритом через 1 год после начала терапии: данные исследования РЕМАРКА. Терапевтический архив. 2018;90(5):22-9 [Korotaeva TV, Loginova EYu, Getiya TS, Nasonov E.L. Results of one-year treat-to-target strategy in early psoriatic arthritis: data of an open-label REMARCA study. Terapevticheskii Arkhiv (Ter. Arkh.). 2018;90(5):22-9 (in Russian)]. DOI:10.26442/terarkh201890522-29
15. Schoels MM, Aletaha D, Alasti F, Smolen JS. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis. 2016;75(5):811. DOI:10.1136/annrheumdis-2015-207507
16. Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465-79. DOI:10.1038/s41584-022-00798-0
17. Landewe RM, van der Heijde D. Use of multidimensional composite scores in rheumatology: parsimony versus subtlety. Ann Rheum Dis. 2021;80:280-5.
DOI:10.1136/annrheumdis-2020-216999
18. Chandran V, Bhella S, Schentag C, Gladman D. Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis. Ann Rheum Dis. 2007;66(7):936-9. DOI:10.1136/ard.2006.065763
19. Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79:700-12. DOI:10.1136/annrheumdis-2020-217159
20. Sunar I, Ataman S, Nas K, et al. Enthesitis and its relationship with disease activity, functional status, and quality of life in psoriatic arthritis: a multi-center study. Rheumatol Int. 2020;40(2):283-94. DOI:10.1007/s00296-019-04480-9
21. Eder L, Farrer C, Jerome D. Is Enthesitis a Marker of Disease Severity in Early Psoriatic Arthritis? Arthritis Rheumatol. 2018;70(10). Available at: https://acrabstracts.org/abstract/is-enthesitis-a-marker-of-disease-severity-in-early-psoriatic-arth... Accessed: 05.09.2022.
22. Mease PJ, Etzel CJ, Huster WJ, et al. Understanding the association between skin involvement and joint activity in patients with psoriatic arthritis: experience from the Corrona Registry. RMD Open. 2019;5:e000867. DOI:10.1136/rmdopen-2018-000867
23. Губарь Е.Е., Корсакова Ю.Л., Логинова Е.Ю., и др. Поражение ногтей при псориатическом артрите. Данные общероссийского регистра. Научно-практическая ревматология. 2021;59(5):563‑70 [Gubar EE, Korsakova YuL, Loginova EYu, et al. Nail disease in psoriatic arthritis. Data from the Russian Psoriatic Arthritis Registry. Rheumatology Science and Practice. 2021;59(5):563-70 (in Russian)]. DOI:10.47360/1995-4484-2021-563-570
24. Mease PJ, Liu M, Rebello S, et al. Association of Nail Psoriasis With Disease Activity Measures and Impact in Psoriatic Arthritis: Data From the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. J Rheumatol. 2021;48(4):520-6. DOI:10.3899/jrheum.19092
25. Reich K, Sullivan J, Arenberger P, et al. Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial. Br J Dermatol. 2019;181(5):954-66. DOI:10.1111/bjd.17351
26. Gulati AM, Semb AG, Rollefstad S, et al. On the HUNT for cardiovascular risk factors and disease in patients with psoriatic arthritis: population-based data from the Nord-Trøndelag Health Study. Ann Rheum Dis. 2016;75(5):819-24. DOI:10.1136/annrheumdis-2014-206824
27. Haroon M, FitzGerald O. Psoriatic arthritis: complexities, comorbidities and implications for the clinic. Expert Rev Clin Immunol. 2016;12(4):405‑16. DOI:10.1586/1744666X.2016.1139453
28. di Minno MN, Peluso R, Iervolino S, et al. Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis. Arthritis Care Res. 2013;65(1):141-7. DOI:10.1002/acr.21711
29. Корсакова Ю.Л., Коротаева Т.В., Логинова Е.Ю., и др. Взаимосвязь ожирения, кардиометаболических нарушений и активности заболевания у больных псориатическим артритом: данные Общероссийского регистра. Терапевтический архив. 2021;93(5):573-80 [Korsakova YuL, Korotaeva TV, Loginova EIu, et al. The relationship between obesity, cardiometabolic disorders and disease activity in psoriatic arthritis patients: data from the Russian register. Terapevticheskii Arkhiv (Ter. Arkh.). 2021;93(5):573-80 (in Russian)]. DOI:10.26442/00403660.2021.05.200789
30. Korsakova Y, Gubar E, Loginova E, et al. The impact of number of comorbidities on achievement remission or low disease activity by DAPSA in psoriatic arthritis. Data from the Russian observational cohort. Ann Rheum Dis. 2022;81(1):871. DOI:10.1136/annrheumdis-2022-eular.3308
31. Корсакова Ю.Л., Логинова Е.Ю., Коротаева Т.В., и др. Бремя прогрессирования псориатического артрита. Данные общероссийского регистра. Терапевтический архив. 2022;94(5):622-7 [Korsakova YuL, Loginova EYu, Korotaeva TV, et al. The burden of progression of psoriatic arthritis. All-Russian register data. Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(5):622-7 (in Russian)]. DOI:10.26442/00403660.2022.05.201506
32. Gossec L, Walsh JA, Michaud K, et al. Impact of Fatigue on Health-Related Quality of Life and Work Productivity in Psoriatic Arthritis: Findings From a Real-World Survey. J Rheumatol. 2022. DOI:10.3899/jrheum.211288
2. Gupta S, Syrimi Z, Hughes DM, Zhao SS. Comorbidities in psoriatic arthritis: asystematic review and meta-analysis. Rheumatol Int. 2021;41(2):275-84.
DOI:10.1007/s00296-020-04775-2
3. Coates LC, Merola JF, Mease PhJ, et al. Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis. Rheumatol. 2021;60:1137-47. DOI:10.1093/rheumatology/keaa271
4. Farkas F, Ikumi N, Elmamoun M, et al. Comparison of Composite Measure Remission Targets in Psoriatic Arthritis. J Rheumatol. 2021;48(8):1272-8. DOI:10.3899/jrheum.200556
5. Wervers K, Luime JJ, Tchetverikov I, et al. Comparison of disease activity measures in early psoriatic arthritis in usual care. Rheumatol (Oxford). 2019;58(12):2251-9. DOI:10.1093/rheumatology/kez215
6. Mumtaz A, Gallagher P, Kirby B, et al. Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis. 2011;70:272-7. DOI:10.1136/ard.2010.129379
7. Helliwell P, FitzGerald O, Fransen J, et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis. 2013;72(2):986-91.
8. Helliwell PJ, Coates LC, FitzGerald O, et al. Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease. Arthritis Res Ther. 2018;20(1):242. DOI:10.1186/s13075-018-1739-0
9. Kumthekar A, Ogdie A. Obesity and Psoriatic Arthritis: A Narrative Review. Rheumatol Ther. 2020;7:447-56. DOI:10.1007/s40744-020-00215-6
10. Ulus Y, Akyol Y, Bilgici1 A, Kuru O. The impact of the presence of fibromyalgia on fatigue in patients with psoriatic arthritis: comparison with controls. Advances Rheumatol. 2020;60:1. DOI:10.1186/s42358-019-0104-6
11. Li Sh-Sh, Du N, He Shi-H, et al. Exploring the Association Between History of Psoriasis (PSO) and Disease Activity in Patients with Psoriatic Arthritis (PsA). Rheumatol Ther. 2022;9(4):1079-90. DOI:10.1007/s40744-022-00455-8
12. Fragoulis GE, Nikiphorou E, McInnes IB, Siebert S. Does Age Matter in Psoriatic Arthritis? A Narrative Review. J Rheumatol. 2022;49(10):1085‑91. DOI:10.3899/jrheum.210349
13. Coates LC, Moverley AR, McParland L, et al. Effect of Tight Control of Inflammation in Early Psoriatic Arthritis (TICOPA): A UK Multicentre, Open-Label, Randomised Controlled Trial. Lancet. 2015;386(10012):2489-98. DOI:10.1016/S0140-6736(15)00347-5
14. Коротаева Т.В., Логинова Е.Ю., Гетия Т.С., Насонов Е.Л. Результаты применения стратегии «Лечение до достижения цели» у больных ранним псориатическим артритом через 1 год после начала терапии: данные исследования РЕМАРКА. Терапевтический архив. 2018;90(5):22-9 [Korotaeva TV, Loginova EYu, Getiya TS, Nasonov E.L. Results of one-year treat-to-target strategy in early psoriatic arthritis: data of an open-label REMARCA study. Terapevticheskii Arkhiv (Ter. Arkh.). 2018;90(5):22-9 (in Russian)]. DOI:10.26442/terarkh201890522-29
15. Schoels MM, Aletaha D, Alasti F, Smolen JS. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis. 2016;75(5):811. DOI:10.1136/annrheumdis-2015-207507
16. Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465-79. DOI:10.1038/s41584-022-00798-0
17. Landewe RM, van der Heijde D. Use of multidimensional composite scores in rheumatology: parsimony versus subtlety. Ann Rheum Dis. 2021;80:280-5.
DOI:10.1136/annrheumdis-2020-216999
18. Chandran V, Bhella S, Schentag C, Gladman D. Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis. Ann Rheum Dis. 2007;66(7):936-9. DOI:10.1136/ard.2006.065763
19. Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79:700-12. DOI:10.1136/annrheumdis-2020-217159
20. Sunar I, Ataman S, Nas K, et al. Enthesitis and its relationship with disease activity, functional status, and quality of life in psoriatic arthritis: a multi-center study. Rheumatol Int. 2020;40(2):283-94. DOI:10.1007/s00296-019-04480-9
21. Eder L, Farrer C, Jerome D. Is Enthesitis a Marker of Disease Severity in Early Psoriatic Arthritis? Arthritis Rheumatol. 2018;70(10). Available at: https://acrabstracts.org/abstract/is-enthesitis-a-marker-of-disease-severity-in-early-psoriatic-arth... Accessed: 05.09.2022.
22. Mease PJ, Etzel CJ, Huster WJ, et al. Understanding the association between skin involvement and joint activity in patients with psoriatic arthritis: experience from the Corrona Registry. RMD Open. 2019;5:e000867. DOI:10.1136/rmdopen-2018-000867
23. Губарь Е.Е., Корсакова Ю.Л., Логинова Е.Ю., и др. Поражение ногтей при псориатическом артрите. Данные общероссийского регистра. Научно-практическая ревматология. 2021;59(5):563‑70 [Gubar EE, Korsakova YuL, Loginova EYu, et al. Nail disease in psoriatic arthritis. Data from the Russian Psoriatic Arthritis Registry. Rheumatology Science and Practice. 2021;59(5):563-70 (in Russian)]. DOI:10.47360/1995-4484-2021-563-570
24. Mease PJ, Liu M, Rebello S, et al. Association of Nail Psoriasis With Disease Activity Measures and Impact in Psoriatic Arthritis: Data From the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. J Rheumatol. 2021;48(4):520-6. DOI:10.3899/jrheum.19092
25. Reich K, Sullivan J, Arenberger P, et al. Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial. Br J Dermatol. 2019;181(5):954-66. DOI:10.1111/bjd.17351
26. Gulati AM, Semb AG, Rollefstad S, et al. On the HUNT for cardiovascular risk factors and disease in patients with psoriatic arthritis: population-based data from the Nord-Trøndelag Health Study. Ann Rheum Dis. 2016;75(5):819-24. DOI:10.1136/annrheumdis-2014-206824
27. Haroon M, FitzGerald O. Psoriatic arthritis: complexities, comorbidities and implications for the clinic. Expert Rev Clin Immunol. 2016;12(4):405‑16. DOI:10.1586/1744666X.2016.1139453
28. di Minno MN, Peluso R, Iervolino S, et al. Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis. Arthritis Care Res. 2013;65(1):141-7. DOI:10.1002/acr.21711
29. Корсакова Ю.Л., Коротаева Т.В., Логинова Е.Ю., и др. Взаимосвязь ожирения, кардиометаболических нарушений и активности заболевания у больных псориатическим артритом: данные Общероссийского регистра. Терапевтический архив. 2021;93(5):573-80 [Korsakova YuL, Korotaeva TV, Loginova EIu, et al. The relationship between obesity, cardiometabolic disorders and disease activity in psoriatic arthritis patients: data from the Russian register. Terapevticheskii Arkhiv (Ter. Arkh.). 2021;93(5):573-80 (in Russian)]. DOI:10.26442/00403660.2021.05.200789
30. Korsakova Y, Gubar E, Loginova E, et al. The impact of number of comorbidities on achievement remission or low disease activity by DAPSA in psoriatic arthritis. Data from the Russian observational cohort. Ann Rheum Dis. 2022;81(1):871. DOI:10.1136/annrheumdis-2022-eular.3308
31. Корсакова Ю.Л., Логинова Е.Ю., Коротаева Т.В., и др. Бремя прогрессирования псориатического артрита. Данные общероссийского регистра. Терапевтический архив. 2022;94(5):622-7 [Korsakova YuL, Loginova EYu, Korotaeva TV, et al. The burden of progression of psoriatic arthritis. All-Russian register data. Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(5):622-7 (in Russian)]. DOI:10.26442/00403660.2022.05.201506
32. Gossec L, Walsh JA, Michaud K, et al. Impact of Fatigue on Health-Related Quality of Life and Work Productivity in Psoriatic Arthritis: Findings From a Real-World Survey. J Rheumatol. 2022. DOI:10.3899/jrheum.211288
________________________________________________
2. Gupta S, Syrimi Z, Hughes DM, Zhao SS. Comorbidities in psoriatic arthritis: asystematic review and meta-analysis. Rheumatol Int. 2021;41(2):275-84.
DOI:10.1007/s00296-020-04775-2
3. Coates LC, Merola JF, Mease PhJ, et al. Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis. Rheumatol. 2021;60:1137-47. DOI:10.1093/rheumatology/keaa271
4. Farkas F, Ikumi N, Elmamoun M, et al. Comparison of Composite Measure Remission Targets in Psoriatic Arthritis. J Rheumatol. 2021;48(8):1272-8. DOI:10.3899/jrheum.200556
5. Wervers K, Luime JJ, Tchetverikov I, et al. Comparison of disease activity measures in early psoriatic arthritis in usual care. Rheumatol (Oxford). 2019;58(12):2251-9. DOI:10.1093/rheumatology/kez215
6. Mumtaz A, Gallagher P, Kirby B, et al. Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis. 2011;70:272-7. DOI:10.1136/ard.2010.129379
7. Helliwell P, FitzGerald O, Fransen J, et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis. 2013;72(2):986-91.
8. Helliwell PJ, Coates LC, FitzGerald O, et al. Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease. Arthritis Res Ther. 2018;20(1):242. DOI:10.1186/s13075-018-1739-0
9. Kumthekar A, Ogdie A. Obesity and Psoriatic Arthritis: A Narrative Review. Rheumatol Ther. 2020;7:447-56. DOI:10.1007/s40744-020-00215-6
10. Ulus Y, Akyol Y, Bilgici1 A, Kuru O. The impact of the presence of fibromyalgia on fatigue in patients with psoriatic arthritis: comparison with controls. Advances Rheumatol. 2020;60:1. DOI:10.1186/s42358-019-0104-6
11. Li Sh-Sh, Du N, He Shi-H, et al. Exploring the Association Between History of Psoriasis (PSO) and Disease Activity in Patients with Psoriatic Arthritis (PsA). Rheumatol Ther. 2022;9(4):1079-90. DOI:10.1007/s40744-022-00455-8
12. Fragoulis GE, Nikiphorou E, McInnes IB, Siebert S. Does Age Matter in Psoriatic Arthritis? A Narrative Review. J Rheumatol. 2022;49(10):1085‑91. DOI:10.3899/jrheum.210349
13. Coates LC, Moverley AR, McParland L, et al. Effect of Tight Control of Inflammation in Early Psoriatic Arthritis (TICOPA): A UK Multicentre, Open-Label, Randomised Controlled Trial. Lancet. 2015;386(10012):2489-98. DOI:10.1016/S0140-6736(15)00347-5
14. Коротаева Т.В., Логинова Е.Ю., Гетия Т.С., Насонов Е.Л. Результаты применения стратегии «Лечение до достижения цели» у больных ранним псориатическим артритом через 1 год после начала терапии: данные исследования РЕМАРКА. Терапевтический архив. 2018;90(5):22-9 [Korotaeva TV, Loginova EYu, Getiya TS, Nasonov E.L. Results of one-year treat-to-target strategy in early psoriatic arthritis: data of an open-label REMARCA study. Terapevticheskii Arkhiv (Ter. Arkh.). 2018;90(5):22-9 (in Russian)]. DOI:10.26442/terarkh201890522-29
15. Schoels MM, Aletaha D, Alasti F, Smolen JS. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis. 2016;75(5):811. DOI:10.1136/annrheumdis-2015-207507
16. Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465-79. DOI:10.1038/s41584-022-00798-0
17. Landewe RM, van der Heijde D. Use of multidimensional composite scores in rheumatology: parsimony versus subtlety. Ann Rheum Dis. 2021;80:280-5.
DOI:10.1136/annrheumdis-2020-216999
18. Chandran V, Bhella S, Schentag C, Gladman D. Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis. Ann Rheum Dis. 2007;66(7):936-9. DOI:10.1136/ard.2006.065763
19. Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79:700-12. DOI:10.1136/annrheumdis-2020-217159
20. Sunar I, Ataman S, Nas K, et al. Enthesitis and its relationship with disease activity, functional status, and quality of life in psoriatic arthritis: a multi-center study. Rheumatol Int. 2020;40(2):283-94. DOI:10.1007/s00296-019-04480-9
21. Eder L, Farrer C, Jerome D. Is Enthesitis a Marker of Disease Severity in Early Psoriatic Arthritis? Arthritis Rheumatol. 2018;70(10). Available at: https://acrabstracts.org/abstract/is-enthesitis-a-marker-of-disease-severity-in-early-psoriatic-arth... Accessed: 05.09.2022.
22. Mease PJ, Etzel CJ, Huster WJ, et al. Understanding the association between skin involvement and joint activity in patients with psoriatic arthritis: experience from the Corrona Registry. RMD Open. 2019;5:e000867. DOI:10.1136/rmdopen-2018-000867
23. Губарь Е.Е., Корсакова Ю.Л., Логинова Е.Ю., и др. Поражение ногтей при псориатическом артрите. Данные общероссийского регистра. Научно-практическая ревматология. 2021;59(5):563‑70 [Gubar EE, Korsakova YuL, Loginova EYu, et al. Nail disease in psoriatic arthritis. Data from the Russian Psoriatic Arthritis Registry. Rheumatology Science and Practice. 2021;59(5):563-70 (in Russian)]. DOI:10.47360/1995-4484-2021-563-570
24. Mease PJ, Liu M, Rebello S, et al. Association of Nail Psoriasis With Disease Activity Measures and Impact in Psoriatic Arthritis: Data From the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. J Rheumatol. 2021;48(4):520-6. DOI:10.3899/jrheum.19092
25. Reich K, Sullivan J, Arenberger P, et al. Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial. Br J Dermatol. 2019;181(5):954-66. DOI:10.1111/bjd.17351
26. Gulati AM, Semb AG, Rollefstad S, et al. On the HUNT for cardiovascular risk factors and disease in patients with psoriatic arthritis: population-based data from the Nord-Trøndelag Health Study. Ann Rheum Dis. 2016;75(5):819-24. DOI:10.1136/annrheumdis-2014-206824
27. Haroon M, FitzGerald O. Psoriatic arthritis: complexities, comorbidities and implications for the clinic. Expert Rev Clin Immunol. 2016;12(4):405‑16. DOI:10.1586/1744666X.2016.1139453
28. di Minno MN, Peluso R, Iervolino S, et al. Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis. Arthritis Care Res. 2013;65(1):141-7. DOI:10.1002/acr.21711
29. Корсакова Ю.Л., Коротаева Т.В., Логинова Е.Ю., и др. Взаимосвязь ожирения, кардиометаболических нарушений и активности заболевания у больных псориатическим артритом: данные Общероссийского регистра. Терапевтический архив. 2021;93(5):573-80 [Korsakova YuL, Korotaeva TV, Loginova EIu, et al. The relationship between obesity, cardiometabolic disorders and disease activity in psoriatic arthritis patients: data from the Russian register. Terapevticheskii Arkhiv (Ter. Arkh.). 2021;93(5):573-80 (in Russian)]. DOI:10.26442/00403660.2021.05.200789
30. Korsakova Y, Gubar E, Loginova E, et al. The impact of number of comorbidities on achievement remission or low disease activity by DAPSA in psoriatic arthritis. Data from the Russian observational cohort. Ann Rheum Dis. 2022;81(1):871. DOI:10.1136/annrheumdis-2022-eular.3308
31. Корсакова Ю.Л., Логинова Е.Ю., Коротаева Т.В., и др. Бремя прогрессирования псориатического артрита. Данные общероссийского регистра. Терапевтический архив. 2022;94(5):622-7 [Korsakova YuL, Loginova EYu, Korotaeva TV, et al. The burden of progression of psoriatic arthritis. All-Russian register data. Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(5):622-7 (in Russian)]. DOI:10.26442/00403660.2022.05.201506
32. Gossec L, Walsh JA, Michaud K, et al. Impact of Fatigue on Health-Related Quality of Life and Work Productivity in Psoriatic Arthritis: Findings From a Real-World Survey. J Rheumatol. 2022. DOI:10.3899/jrheum.211288
Авторы
Ю.Л. Корсакова*1, Т.В. Коротаева1, Е.Ю. Логинова1, Е.Е. Губарь1, Л.Д. Воробьева1, С.И. Глухова1, Е.Л. Насонов1,2
1 ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой», Москва, Россия;
2 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия
*yulkorsakova@bk.ru
1 Nasonova Research Institute of Rheumatology, Moscow, Russia;
2 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
*yulkorsakova@bk.ru
1 ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой», Москва, Россия;
2 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия
*yulkorsakova@bk.ru
________________________________________________
1 Nasonova Research Institute of Rheumatology, Moscow, Russia;
2 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
*yulkorsakova@bk.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.